Stocks · News reference

Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion

Aug 24, 2026, 8:05 PMHenry Khederian

Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 24, 2026, 8:05 PM
Checked: Aug 24, 2026, 8:05 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 24, 2026, 3:02 PMBenzinga Newsdesk
Biomea Fusion shares are trading higher after the company announced the completion of enrollment in COVALENT-211 Phase II clinical trial evaluating icovamenib in insulin-deficient Type 2 diabetes.
Read original at benzinga
BMEA
BenzingaAug 13, 2026, 11:04 AMBenzinga Newsdesk
Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults
Read original at benzinga
BMEA
BenzingaAug 5, 2026, 10:11 PMBenzinga Newsdesk
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of $(0.51) per share from
Read original at benzinga
BMEA